



KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED

Our Company was incorporated as 'Jagjit Singh and Sons Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, Maharashtra at Mumbai on July 26, 1973. Our Company changed the location of its registered office from the State of Maharashtra to the erstwhile State of Andhra Pradesh, pursuant to an order dated January 29, 2003 by the Company Law Board, Western Region Bench, Mumbai ("Order") and the registration of the Order vide certificate of registration dated February 21, 2003 by the Registrar of Companies, Andhra Pradesh and Telangana (then the Registrar of Companies, Andhra Pradesh) ("RoC"). Subsequently, the name of our Company was changed to 'Krishna Institute of Medical Sciences Private Limited', pursuant to a letter of approval from the Central Government dated January 2, 2004 and a fresh certificate of incorporation issued by the RoC on January 2, 2004. Further, pursuant to the conversion of our Company to a public limited company, our name was changed to 'Krishna Institute of Medical Sciences Limited' and the RoC issued a fresh certificate of incorporation on January 29, 2004. For further details, see "History and Certain Corporate Matters" on page 198 of the Red Herring Prospectus dated June 9, 2021 and the addendum and corrigendum dated June 12, 2021 and June 15, 2021 to the Red Herring Prospectus (together, the "RHP").

Registered and Corporate Office: D. No. 1-8-31/1, Minister's Road, Secunderabad - 3, Telangana - 500 003, India; **Tel:** +91 40 4418 6000; **Website:** www.kimshospitals.com; **Contact Person:** Umashankar Mantha, Company Secretary and Compliance Officer; **E-mail:** cs@kimshospitals.com; **Corporate Identity Number:** U55101TG1973PLC040558

OUR PROMOTERS: DR. BHASKARA RAO BOLLINENI, RAJYASRI BOLLINENI, DR. ABHINAV BOLLINENI, ADWIK BOLLINENI AND BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 2,000.00 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 23,560,538 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER FOR SALE"), COMPRISING UP TO 16,003,615 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY GENERAL ATLANTIC SINGAPORE KH PTE. LTD (THE "INVESTOR SELLING SHAREHOLDER"), UP TO 387,966 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY DR. BHASKARA RAO BOLLINENI, UP TO 775,933 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY RAJYASRI BOLLINENI, UP TO 387,966 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED (COLLECTIVELY, THE "PROMOTER SELLING SHAREHOLDERS"), 6,005,058 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY PERSONS REFERRED TO IN ANNEXURE A, PROVIDED ON PAGE 412 OF THE RHP (REFERRED TO AS THE "OTHER SELLING SHAREHOLDERS"), TOGETHER WITH THE INVESTOR SELLING SHAREHOLDER AND PROMOTER SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS", AND SUCH EQUITY SHARES THE "OFFERED SHARES").

THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES, AGGREGATING UP TO ₹ 200.00 MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS "NET OFFER". THE OFFER AND NET OFFER SHALL CONSTITUTE [●]% AND [●]%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

QIB Portion: Not Less than 75% of the Offer | Retail Portion: Not more than 10% of the Offer | Non-Institutional Portion: Not more than 15% of the Offer
Employee Reservation Portion: Up to [●] Equity Shares aggregating up to ₹ 200 million

Price Band: ₹ 815 to ₹ 825 per Equity Share of face value of ₹10 each.

A discount of ₹ 40 per Equity Share is being offered to Eligible Employees Bidding in the Employee Reservation Portion
The Floor Price is 81.50 times the face value of the Equity Shares and the Cap Price is 82.50 times the face value of the Equity Shares.
Bids can be made for a minimum of 18 Equity Shares and in multiples of 18 Equity Shares thereafter.

ASBA*

Simple, Safe, Smart way of Application!!!

*Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details, check section on ASBA below.
Mandatory in public issues. No cheque will be accepted.



UPI-Now available in ASBA for Retail Individual Bidders ("RIBs") applying through Registered Brokers, DPs and RTAs. RIBs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Investors are required to ensure that the bank account used for bidding is linked to their PAN.

• ASBA has to be availed by all the investors except Anchor Investors. UPI may be availed by RIBs. • For details on the ASBA and UPI process, please refer to the details given in ASBA Form and abridged prospectus and also please refer to the section "Offer Procedure" beginning on page 381 of the RHP. • The process is also available on the website of Association of Investment Bankers of India "AIBI", BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE"), and together with BSE, the "Stock Exchanges") and in the General Information Document. ASBA Forms can be downloaded from the websites of the Stock Exchanges and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in. List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. • For RIBs Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intlmd=40) and (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intlmd=43) respectively, as updated from time to time. HDFC Bank Limited has been appointed as Sponsor Bank for the Offer. For issue related queries, investors may contact: the Book Running Lead Managers ("BRLMs") and Registrar to the Offer on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and Mail Id: ipo.upi@npci.org.in.

Risks to Investors

- 1. Average cost of acquisition of Equity Shares held by the Selling Shareholders ranges from ₹ 5.15 per Equity Share to ₹ 360.00 per Equity Share and Offer Price at upper end of the Price Band is ₹ 825.**
- 2. The Price/Earnings ratio based on diluted EPS on a restated consolidated basis for Fiscal 2021 for the Issuer at the upper end of the Price Band is 31.23x. For our peer group, three companies have negative earnings per share for Fiscal 2021 and accordingly the Price/Earnings ratio for them is not applicable. Only one company in the peer group has positive earnings per share and accordingly the Price/Earnings ratio for the respective company is 101.39x for Fiscal 2020.**
- 3. The four book running lead managers ("BRLMs") associated with the Offer have handled 29 public issues in the past three years, out of which 10 issues closed below the issue price on listing date.**
- 4. Weighted Average Return on Net Worth for Fiscals 2021, 2020, 2019 is 16.82%.**

BID/OFFER PROGRAMME

OPEN CLOSES ON: FRIDAY, JUNE 18, 2021*

*UPI mandate end time and date shall be at 12:00 pm on Monday, June 21, 2021.

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after revision of the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, in consultation with the Book Running Lead Managers, may, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a press release, and also by indicating the change on the respective websites of the Book Running Lead Managers and at the terminals of the members of the Syndicate and by an intimation to Designated Intermediaries and the Sponsor Bank, as applicable.

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process, in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Net Offer will be Allotted on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), our IPO Committee, in consultation with the Book Running Lead Managers, has allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third was reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Price"). Further, 5% of the Net QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIBs (excluding the Anchor Investor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be Allotted to QIBs, then the entire application money will be refunded forthwith. Further, not more than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not more than 10% of the Net Offer shall be available for allocation to RIBs, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, Equity Shares may be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 381 of the RHP.

Bidders/Applicants should ensure that DP ID, PAN and the Client ID and UPI ID (if applicable, in case RIBs) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorized the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from

failure to update the Demographic Details would be at the Bidders/Applicants' sole risk.

Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects and other objects of the Company, see "History and Certain Corporate Matters" on page 198 of the RHP and Clause III of the Memorandum of Association of the Company. The Memorandum of Association of the Company is a material document for inspection in relation to the Offer. For further details, see "Material Contracts and Documents for Inspection" on page 404 of the RHP.

Liability of the members of the Company: Limited by shares

Amount of share capital of the Company and capital structure: The authorised, issued, subscribed and paid up share capital of the Company as on the date of the RHP is as follows: The authorised share capital of the Company is ₹ 950,000,000 divided into 95,000,000 Equity Shares of ₹ 10 each. The issued, subscribed and paid-up share capital of the Company is ₹ 775,932,830 divided into 77,593,283 Equity Shares of ₹ 10 each. For details, please see the section entitled "Capital Structure" beginning on page 85 of the RHP.

Names of signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed by them: Given below are the names of the signatories of the Memorandum of Association of the Company, at the time of signing of the Memorandum of Association: Jagjit Singh and Vimla Swami. For further details please see "Capital Structure" on page 85 of the RHP.

Listing : The Equity Shares offered through the RHP are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from BSE and NSE for the listing of the Equity Shares pursuant to letters dated March 23, 2021 and March 24, 2021, respectively. For the purposes of the Offer, BSE is the Designated Stock Exchange. A signed copy of the RHP has been delivered to the RoC and the Prospectus shall be delivered to the RoC in accordance with Section 26(4) of the Companies Act 2013. For details of the material contracts and material documents available for inspection from the date of the RHP up to the Bid/Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 404 of the RHP.

Disclaimer Clause of the SEBI: SEBI only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities or the offer document. The investors are advised to refer to page 361 of the RHP for the full text of the Disclaimer Clause of SEBI.

Disclaimer Clause of BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the RHP has been cleared or approved by BSE nor does it certify, warrant or endorse the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 362 of the RHP for the full text of the Disclaimer Clause of BSE.

Disclaimer Clause of NSE : It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it warrant, certify or endorse the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 362 of the RHP for the full text of the Disclaimer Clause of NSE.

General Risks: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the RHP. Specific attention of the investors is invited to "Risk Factors" on page 28 of the RHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
 Investment Banking	 AXIS CAPITAL	 CREDIT SUISSE	 IIFL SECURITIES	 LINKintime	Umashankar Mantha D. No. 1-8-31/1, Minister's Road, Secunderabad - 3, Telangana - 500 003, India. Telephone: +91 40 4418 6433 E-mail: cs@kimshospitals.com
Kotak Mahindra Capital Company Limited 27 BKC, 1st Floor, Plot No. C – 27, 'G' Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051, Maharashtra, India Tel: +91 22 4336 0000 E-mail: kims.ipo@kotak.com Website: www.investmentbank.kotak.com Investor Grievance ID: kmccredressal@kotak.com Contact Person: Ganesh Rane SEBI Registration Number: INM000008704	Axis Capital Limited 1st Floor, Axis House, C-2, Wadia International Centre, P.B. Marg, Worli, Mumbai 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: kims.ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Ankit Bhatia SEBI Registration Number: INM000012029	Credit Suisse Securities (India) Private Limited Ceejay House, 10th Floor, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai 400 018, Maharashtra, India. Tel: +91 22 6777 3777 E-mail: list.kimsipo@credit-suisse.com Website: https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html Investor Grievance ID: list.icgcellmerbnkg@credit-suisse.com Contact Person: Chunky Shah SEBI Registration Number: INM000011161	IIFL Securities Limited 10th Floor, IIFL Centre, Kamala City, Senapati Bapat Marg, Lower Parel (West), Mumbai 400 013 Maharashtra, India Tel: +91 22 4646 4600 E-mail: kims.ipo@iiflcap.com Website: www.iiflcap.com Investor Grievance ID: ig.ib@iiflcap.com Contact person: Shirish Chikalge / Keyur Ladhawala SEBI Registration Number: INM000010940	Link Intime India Private Limited C-101, 247 Park L B S Marg, Vikhroli (West) Mumbai 400 083, Maharashtra, India Tel: +91 22 4918 6200 E-mail: kims.ipo@linkintime.co.in Website: www.linkintime.co.in Investor grievance ID: kims.ipo@linkintime.com Contact Person: Shanti Gopalkrishnan SEBI Registration Number: INR000004058	Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-Offer or post-Offer related grievances including non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non- receipt of refund orders or non-receipt of funds by electronic mode, etc.

AVAILABILITY OF RHP: Investors are advised to refer to the RHP and the Risk Factors, contained therein before applying in the Offer. Full copy of the RHP is available on website of SEBI at www.sebi.gov.in, websites of the BRLMs, i.e. Kotak Mahindra Capital Company Limited, Axis Capital Limited, Credit Suisse Securities (India) Private Limited and IIFL Securities Limited at www.investmentbank.kotak.com, www.axiscapital.co.in, https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html and www.iiflcap.com, respectively and websites of BSE and NSE i.e. www.bseindia.com and www.nseindia.com, respectively.

AVAILABILITY OF BID CUM APPLICATION FORMS: Bid cum Application Forms can be obtained from the Registered Office of KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED, Tel: +91 40 4418 6000; Book Running Lead Managers: **Kotak Mahindra Capital Company Limited**, Tel: +91 22 4336 0000, **Axis Capital Limited**, Tel: +91 22 4325 2183, **Credit Suisse Securities (India) Private Limited**, Tel: +91 22 6777 3777 and **IIFL Securities Limited**, Tel: +91 22 4646 4600 and **Syndicate Members: Kotak Securities Limited**, Tel: +91 22 6218 5470 and at the select locations of the Sub-syndicate Members, SCSBs, Registered Brokers, RTAs and CDPs participating in the Offer. ASBA Forms will also be available on the websites of BSE and NSE and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exchanges and SEBI.

Sub-Syndicate Members: Almondz Global Securities Limited, Amrapali Capital & Finance Services Limited, Anand Rathi Share & Stock Brokers Limited, Anand Share Consultancy, ANS Pvt. Limited, Ashwani Dandia & Co., Axis Securities Limited, Bonanza Portfolio Limited, Centrum Broking Limited, Dalal & Broacha Stock Broking Pvt. Limited, Edelweiss Broking Limited, G Raj & Co. (Consultants) Limited, Globe Capital Market Limited, ICICI Securities Limited, Jhaveri Securities, JM Financial Services Limited, Jobanputra Financial Services Private Limited, Kalpataru Multiplier Limited, LKP Securities Limited, Marwadi Shares & Finance, Motilal Oswal Financial Services Limited, Motilal Oswal Securities Limited, Nirmal Bang Securities Pvt. Ltd., Patel Wealth Advisors Pvt. Limited, Prabhudas Lilladher Pvt. Limited, Pravin Ratilal Share & Stock Brokers Limited, RR Equity Brokers Pvt. Limited, SBICap Securities Limited, Sharekhan Limited, SMC Global Securities Limited, Tanna Financial Services, Way2Wealth Brokers Private Limited, YES Securities (India) Limited

Escrow Collection Bank, Refund Bank and Public Offer Account Bank: HDFC Bank Limited | **Sponsor Bank:** HDFC Bank Limited
All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

For KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED
On behalf of the Board of Directors

Sd/-

Company Secretary and Compliance Officer

Place: Secunderabad
Date: June 16, 2021

KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with the Registrar of Companies, Telangana at Hyderabad. The RHP shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs i.e. Kotak Mahindra Capital Company Limited, Axis Capital Limited, Credit Suisse Securities (India) Private Limited and IIFL Securities Limited at www.investmentbank.kotak.com, www.axiscapital.co.in, https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html and www.iiflcap.com, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 28 of the RHP. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision.

This advertisement is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Krishna Institute of Medical Sciences Limited does not intend to register any part of the proposed offering of securities in the United States or to conduct a public offering of securities in the United States.